Brenipatide vs Maridebart cafraglutide
A once-monthly dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale. GLP-1 agonism paired with GIP receptor antagonism — the opposite GIP direction to tirzepatide. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Brenipatide LY3537031 | Maridebart cafraglutide MariTide | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Investigational | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GIP/GLP-1 dual agonist (acylated peptide) | GLP-1 agonist–GIP-antagonist peptide–antibody conjugate |
| Receptor | GIP + GLP-1 receptors | GLP-1 receptor (agonist) + GIP receptor (antagonist) |
| Molecular weight | ≈4,900 Da | ≈150,000 Da |
| Half-life | engineered for once-monthly dosing | |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Brenipatide and Maridebart cafraglutide?
- Brenipatide is an engineered analog based on Glucagon-like peptide-1; Maridebart cafraglutide is an engineered analog based on Glucagon-like peptide-1. Brenipatide signals at GIP + GLP-1 receptors; Maridebart cafraglutide signals at GLP-1 receptor (agonist) + GIP receptor (antagonist).
- How do the half-lives of LY3537031 and MariTide compare?
- The reported circulating half-life of Brenipatide is engineered for once-monthly dosing; Maridebart cafraglutide is ~21 days (monthly dosing). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Maridebart cafraglutide vs Brenipatide. Or open the interactive comparison tool to add more molecules.